Connect with us

Technology

NUTEX HEALTH REPORTS THIRD QUARTER AND YEAR TO DATE SEPTEMBER 30, 2024 FINANCIAL RESULTS

Published

6 hours ago

on

TOTAL REVENUE OF $222.3 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $178.0 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE OF 25%HOSPITAL DIVISION VISITS OF 122,944 FOR THE FIRST NINE MONTHS OF 2024 VS. VISITS OF 102,798 FOR THE SAME PERIOD IN 2023, AN INCREASE OF 20%HOSPITAL DIVISION OPERATING INCOME OF $54.7 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $21.1 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE OF 159%NET CASH FROM OPERATING ACTIVITIES OF $23.1 MILLION FOR THE FIRST NINE MONTHS OF 2024COMPANY CONTINUES ITS FOCUS ON INCREASING CASH FLOW

HOUSTON, Nov. 7, 2024 /PRNewswire/ — Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in ten states and primary care-centric, risk-bearing physician networks, today announced third quarter 2024 financial results for the three and nine months ended September 30, 2024.

Financial Highlights for the Three Months Ended September 30, 2024:

Total revenue of $78.8 million as compared to total revenue of $62.7 million for the three months ended September 30, 2023, an increase of 26%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 20.7% in 2024 compared to the same period in 2023.Operating income (including the negative impact of a $2.0 million non-cash stock-based compensation expense) for the three months ended September 30, 2024 was $9.7 million, compared to an operating loss of approximately $0.8 million for the three months ended September 30, 2023, representing a $10.5 million improvement quarter over quarter.Net loss attributable to Nutex Health of $8.8 million in the three months ended September 30, 2024 as compared to a net loss attributable to Nutex Health of $5.5 million for the three months ended September 30, 2023. This $8.8 million amount includes a $6.7 million non-cash loss on warrant liability as well as the $2.0 million non-cash stock-based compensation expense noted above.EBITDA attributable to Nutex Health of $4.3 million, as compared to EBITDA attributable to Nutex Health of $1.2 million for the three months ended September 30, 2023.Adjusted EBITDA attributable to Nutex Health of $13.5 million, as compared to Adjusted EBITDA attributable to Nutex Health of $1.3 million for the three months ended September 30, 2023, an increase of 938%.Total visits from the Hospital Division were 41,668 for the third quarter 2024, as compared to 37,443 for the third quarter 2023, an increase of 4,225 or 11.3%. Of this visit growth, mature hospitals increased by 3.8% in 2024 compared to the same period in 2023.

Financial Highlights for the Nine Months Ended September 30, 2024:

Total revenue of $222.3 million as compared to total revenue of $178.0 million for the nine months ended September 30, 2023, an increase of approximately 25%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 13.5% in 2024 compared to 2023.Operating income for the nine months ended September 30, 2024 was $16.4 million compared to an operating loss of $5.6 million for the nine months ended September 30, 2023, representing a $22.0 million improvement year over year.Net loss attributable to Nutex Health of $9.5 million as compared to net loss attributable to Nutex Health of $14.2 million for the nine months ended September 30, 2023. This $9.5 million amount includes non-cash items of $10.2 million (non-cash stock-based compensation expense of $2.0 million, non-cash impairment of assets of $3.9 million, non-cash impairment of goodwill of $3.2 million and $1.1 million non-cash loss on warrant liability) in the first nine months of 2024, while the $14.2 million amount includes non-cash stock-based compensation expense of $2.2 million in the first nine months of 2023.EBITDA attributable to Nutex Health of $19.9 million, as compared to EBITDA attributable to Nutex Health of $5.3 million for the nine months ended September 30, 2023.Adjusted EBITDA attributable to Nutex Health of $30.1 million, as compared to Adjusted EBITDA attributable to Nutex Health of $7.7 million for the nine months ended September 30, 2023, an increase of 290%.Total visits from the Hospital Division were 122,944 for the nine months ended September 30, 2024, as compared to 102,798 for the same period in 2023, an increase of 20,146 or 19.6%. Of this visit growth, mature hospitals increased by 7.7% in the nine months ended September 30, 2024 compared to the same period in 2023.Net cash from operating activities of $23.1 million for the nine months ended September 30, 2024. As of September 30, 2024, the Company had total assets of $438.5 million, including cash and cash equivalents of $46.9 million and long-term debt of $26.8 million.

Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.

“We are pleased to report 25% revenue growth, Adjusted EBITDA attributable to Nutex Health of $13.5 million and a 209% increase in gross profit to $21.9 million in the third quarter ended September 30, 2024, showing our continued focus on top line growth, increasing cash flow as well as improving profitability,” stated Jon Bates, Chief Financial Officer of Nutex Health.

“Nutex Health had another outstanding quarter. The strategic and operational decisions we have made over the last nine months are driving this strong performance, as demonstrated by another quarter of year-over-year growth in revenue, EBITDA and Adjusted EBITDA as well as incremental growth in cash flow. We are confident that our momentum will continue and plan on growing our hospital and population health divisions responsibly as we drive value for our shareholders,” stated Warren Hosseinion, M.D., President of Nutex Health.

“The four de-novo hospitals that we opened in 2023 are ramping up nicely, resulting in strong year-over-year growth in both revenue and patient volume. Volumes and revenue continue to increase among our mature hospitals, both on the outpatient side as well as the inpatient side, which still have excess capacity. Our average payment by insurers of patient claims also increased, a trend we are optimistic will persist as we continue to work the NSA (No Surprises Act) claims through the Independent Dispute Resolution process,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.

For more details on the Company’s Third Quarter 2024 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30, 2024

December 31, 2023

Assets

Current assets:

Cash and cash equivalents

$

46,909,281

$

22,002,056

Accounts receivable

62,745,336

58,624,301

Accounts receivable – related parties

3,602,189

4,152,068

Inventories

2,259,168

3,390,584

Prepaid expenses and other current assets

4,279,360

2,679,394

Total current assets

119,795,334

90,848,403

Property and equipment, net

78,246,467

81,387,649

Operating right-of-use assets

11,442,369

11,853,082

Finance right-of-use assets

198,462,381

176,146,329

Intangible assets, net

15,855,392

20,512,636

Goodwill, net

13,918,719

17,066,263

Other assets

767,942

431,135

Total assets

$

438,488,604

$

398,245,497

Liabilities and Equity

Current liabilities:

Accounts payable

$

10,320,933

$

18,899,196

Accounts payable – related parties

6,342,883

6,382,197

Lines of credit

3,384,517

3,371,676

Current portion of long-term debt

10,499,532

10,808,721

Operating lease liabilities, current portion

2,060,758

1,579,987

Finance lease liabilities, current portion

5,261,458

4,315,979

Accrued expenses and other current liabilities

29,688,665

12,955,296

Total current liabilities

67,558,746

58,313,052

Long-term debt, net

26,801,811

26,314,733

Warrant liability

5,715,143

–

Operating lease liabilities, net

14,307,320

15,479,639

Finance lease liabilities, net

240,924,194

213,886,213

Deferred tax liabilities

3,402,965

5,145,754

Total liabilities

358,710,179

319,139,391

Commitments and contingencies

Equity:

Common stock, $0.001 par value; 950,000,000 shares authorized; 5,215,709 and 4,511,199
shares issued and outstanding as of September 30, 2024 and December 31, 2023,
respectively

5,216

4,511

Additional paid-in capital

479,024,452

470,521,218

Accumulated deficit

(418,588,975)

(409,072,539)

Nutex Health Inc. equity

60,440,693

61,453,190

Noncontrolling interests

19,337,732

17,652,916

Total equity

79,778,425

79,106,106

Total liabilities and equity

$

438,488,604

$

398,245,497

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

 

Three Months Ended September 30, 

Nine Months Ended September 30, 

2024

2023

2024

2023

Revenue:

Hospital division

$

71,732,529

$

54,585,263

$

199,366,776

$

155,485,230

Population health management division

7,062,340

8,137,709

22,964,141

22,491,613

Total revenue

78,794,869

62,722,972

222,330,917

177,976,843

Operating costs and expenses:

Payroll and benefits

29,848,083

28,873,144

85,249,302

79,570,519

Contract services

11,657,010

9,035,650

32,481,686

27,972,854

Medical supplies

3,982,598

3,460,130

12,892,904

10,748,214

Depreciation and amortization

4,972,478

4,745,941

13,691,484

12,908,848

Other

6,417,886

9,541,894

23,380,318

25,215,549

Total operating costs and expenses

56,878,055

55,656,759

167,695,694

156,415,984

Gross profit

21,916,814

7,066,213

54,635,223

21,560,859

Corporate and other costs:

Facilities closing costs

–

–

–

217,266

Acquisition costs

–

43,464

–

43,464

Stock-based compensation expense

1,963,518

49,167

1,951,444

2,198,812

Impairment of assets

425,221

–

3,898,856

–

Impairment of goodwill

–

–

3,197,391

–

General and administrative expenses

9,865,330

7,794,808

29,176,130

24,730,168

Total corporate and other costs

12,254,069

7,887,439

38,223,821

27,189,710

Operating income (loss)

9,662,745

(821,226)

16,411,402

(5,628,851)

Interest expense, net

5,381,040

4,098,179

14,879,934

12,081,316

Loss on warrant liability

6,733,552

–

1,072,709

–

Other (income) expense

128,645

(53,206)

(712,049)

70,721

Income (loss) before taxes

(2,580,492)

(4,866,199)

1,170,808

(17,780,888)

Income tax expense (benefit)

4,584,518

(342,259)

5,868,075

(2,068,530)

Net loss

(7,165,010)

(4,523,940)

(4,697,267)

(15,712,358)

Less: net income (loss) attributable to
noncontrolling interests

1,623,303

1,018,451

4,819,169

(1,543,641)

Net loss attributable to Nutex Health Inc.

$

(8,788,313)

$

(5,542,391)

$

(9,516,436)

$

(14,168,717)

Loss per common share:

Basic

$

(1.72)

$

(1.25)

$

(1.91)

$

(3.23)

Diluted

$

(1.72)

$

(1.25)

$

(1.91)

$

(3.23)

 

NUTEX HEALTH INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Nine Months Ended September 30, 

2024

2023

Cash flows from operating activities:

Net income (loss)

$

(4,697,267)

$

(15,712,358)

Adjustments to reconcile net loss to net cash from operating activities:

Depreciation and amortization

13,691,484

12,908,848

Loss on warrant liability

1,072,709

–

Impairment of goodwill

3,197,391

–

Impairment of assets

3,898,856

–

Derecognition of goodwill

453,017

–

Stock-based compensation expense

1,951,444

2,198,812

Deferred tax benefit

(1,742,789)

(2,068,530)

Debt accretion expense

804,760

1,251,867

Loss on lease termination

–

58,210

Non-cash lease expense (income)

(280,835)

89,338

Changes in operating assets and liabilities, net of the effects of acquisitions:

Accounts receivable

(4,253,034)

4,444,706

Accounts receivable – related party

549,879

(949,408)

Inventories

1,131,416

850,569

Prepaid expenses and other current assets

(1,360,721)

(3,771,946)

Accounts payable

(7,975,067)

(6,015,250)

Accounts payable – related party

(39,314)

2,228,527

Accrued expenses and other current liabilities

16,698,416

7,519,285

Net cash from operating activities

23,100,345

3,032,670

Cash flows from investing activities:

Acquisitions of property and equipment

(1,908,651)

(10,322,487)

Cash related to sale of business

(361,325)

–

Payments for acquisitions of businesses, net of cash acquired

–

(743,837)

Cash related to deconsolidation of Real Estate Entities

–

(1,039,157)

Net cash from investing activities

(2,269,976)

(12,105,481)

Cash flows from financing activities:

Proceeds from lines of credit

1,132,168

2,340,911

Proceeds from notes payable

7,014,999

16,952,905

Proceeds from convertible notes

–

891,000

Repayments of lines of credit

(1,119,327)

(1,592,714)

Repayments of notes payable

(8,332,482)

(10,557,758)

Repayments of finance leases

(1,923,687)

(2,704,082)

Proceeds from common stock issuance, net issuance costs

9,202,500

–

Proceeds from exercise of warrants

801,000

–

Members’ contributions

960,913

649,550

Members’ distributions

(3,659,228)

(4,335,532)

Net cash from financing activities

4,076,856

1,644,280

Net change in cash and cash equivalents

24,907,225

(7,428,531)

Cash and cash equivalents – beginning of the period

22,002,056

34,255,264

Cash and cash equivalents – end of the period

$

46,909,281

$

26,826,733

 

Non-GAAP Financial Measures (Unaudited)

EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.

We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.

We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for an allocation to noncontrolling interests, (gain)/loss on warrant liability, stock-based compensation, certain defined items of expense, and any acquisition-related costs and impairments. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below. EBITDA and Adjusted EBITDA are not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.

Three Months Ended September 30, 

Nine Months Ended September 30, 

2024

2023

2024

2023

Reconciliation of net loss attributable to Nutex Health
Inc. to Adjusted EBITDA:

Net loss attributable to Nutex Health Inc.

$

(8,788,313)

$

(5,542,391)

$

(9,516,436)

$

(14,168,717)

Depreciation and amortization

4,972,478

4,745,941

13,691,484

12,908,848

Interest expense, net

5,381,040

4,098,179

14,879,934

12,081,316

Income tax expense (benefit)

4,584,518

(342,259)

5,868,075

(2,068,530)

Allocation to noncontrolling interests

(1,808,422)

(1,772,908)

(4,980,424)

(3,500,873)

EBITDA attributable to Nutex Health Inc.

4,341,301

1,186,562

19,942,633

5,252,044

Facilities closing costs

–

–

–

217,266

Loss on warrant liability

6,733,552

–

1,072,709

–

Impairment of assets

425,221

3,898,856

Impairment of goodwill

–

–

3,197,391

–

Acquisition costs

–

43,464

–

43,464

Stock-based compensation expense

1,963,518

49,167

1,951,444

2,198,812

Adjusted EBITDA attributable to Nutex Health Inc.

$

13,463,592

$

1,279,193

$

30,063,033

$

7,711,586

 

About Nutex Health Inc.

Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.

The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 22 facilities in ten states.

The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act , economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2023 and in the Quarterly Reports on Form 10-Q for the periods ending March 31, 2024 and June 30, 2024 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-third-quarter-and-year-to-date-september-30-2024-financial-results-302299409.html

SOURCE Nutex Health, Inc.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

GoSchool: Redefining Inclusive Education for Special Learning Needs

Published

34 mins ago

on

November 8, 2024

By

MUMBAI, India, Nov. 8, 2024 /PRNewswire/ — GoSchool, a progressive international online school, is breaking new ground to ensure that every child, irrespective of their learning needs, has access to high-quality education. Serving students with ADHD, high-functioning autism, dyslexia, and physical disabilities, GoSchool’s inclusive approach fosters a nurturing, personalized, and adaptable learning environment.

In today’s fast-paced world, traditional schools often struggle to meet the unique requirements of students with special learning needs. GoSchool’s innovative online platform offers a supportive and flexible learning space that empowers these students to reach their fullest potential.

Why GoSchool is the Ideal Choice:

Children with special learning needs often face significant challenges in traditional classroom settings, from difficulties in social interactions and sensory processing to the need for tailored educational approaches. GoSchool addresses these challenges through a variety of innovative solutions:

Specialized Teachers and Support Staff
GoSchool employs dedicated educators who are specifically trained to support children with special learning needs. These teachers understand the complexities of neurodivergent behaviors and are adept at fostering an inclusive classroom environment. Their expertise enables them to effectively guide students, offering them the tools and encouragement they need to succeed academically.Alleviating Social Anxiety Through Online Learning
For children dealing with social anxiety, traditional school environments can feel overwhelming. GoSchool’s online platform enables children to learn from the comfort of their homes, creating a safe space that reduces anxiety and encourages engagement. This approach is especially beneficial for children with autism or social anxiety, who may find in-person interactions challenging.Small Class Sizes for Personalized Attention
GoSchool maintains small class sizes to ensure each student receives individualized attention. With fewer students per class, teachers can tailor their instruction, closely monitor each child’s progress, and make necessary adjustments that enhance the overall learning experience.High Academic Standards Without Compromise
Despite its inclusive and personalized approach, GoSchool adheres to the highest academic standards. Affiliated with Cambridge International and Pearson Edexcel, GoSchool offers a rigorous curriculum designed to prepare students for academic success, college readiness, and lifelong learning. The curriculum is structured to deliver a robust educational experience while allowing flexibility in teaching methods for students who require additional support.An Ideal Alternative to Homeschooling
GoSchool provides the best of both worlds: the flexibility and one-on-one support often found in homeschooling, combined with the academic rigor, structure, and social interaction opportunities of an international school. This unique approach makes GoSchool an excellent option for parents seeking more than a traditional or home-based education.

A Commitment to Individual Growth and Excellence

GoSchool believes that children with special learning needs have tremendous potential and simply need the right environment to flourish. By blending technology, specialized teaching methods, and a supportive community, GoSchool aims to redefine inclusive education. With a curriculum designed to promote both academic achievement and personal growth, GoSchool equips students with the skills and confidence they need to succeed in today’s world.

Ready to Empower every Child:

GoSchool believes in nurturing every child’s unique potential within a learning environment where they feel valued and supported. If parents are seeking a school that truly understands and meets the specific needs of their child, GoSchool could be the perfect fit. Parents can enrol today to give their child the opportunity to thrive in a school that champions inclusivity, high standards, and innovative education.

To learn more or start the enrollment process, visit www.go-school.in and begin the child’s journey to success.

Contact Us: +91 91794 69179
Email: admission@go-school.in
Dr. Thomas V Aghamkar | +91 8055870956 | thomas.aghamkar@go-education.in

Photo: https://mma.prnewswire.com/media/2551307/Special_Learning_Needs_GoSchool.jpg
Logo: https://mma.prnewswire.com/media/2551306/GoSchool_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/goschool-redefining-inclusive-education-for-special-learning-needs-302298578.html

Continue Reading

Technology

Global Battery Alliance Unveils Results of Wave Two Battery Passport Pilots, Two CATL Programs Included

Published

34 mins ago

on

November 8, 2024

By

NINGDE, China, Nov. 8, 2024 /PRNewswire/ — The Global Battery Alliance (GBA) today successfully unveiled the results of the 2024 Battery Passport pilots during the Annual General Meeting, hosted in Shanghai and Ningde. Ten consortia, led by the world’s leading battery cell manufacturers, successfully completed the largest pre-competitive effort to establish harmonized battery passport. As a member of the GBA, CATL supported this initiative by leading two pilot projects for its Shenxing and CTP batteries, achieving a new milestone towards more transparent and sustainable battery value chains.

In January 2023, GBA published the world’s first battery passport proof of concept in Davos, Switzerland during the World Economic Forum Annual Meeting. Building on the successful launch in 2023, the consortia worked with seven digital solution providers to determine the provenance and flow of seven materials: lithium, graphite (artificial), aluminum, cobalt, copper, iron phosphate, and nickel.

Aligning with existing regulations and voluntary standards, seven rulebooks were developed through a multi-stakeholder process by the GBA, including Greenhouse Gas Emissions, Biodiversity, and Circular Design.

With separate passports for its Shenxing and CTP batteries, CATL was one of the first companies to share its results from the pilots with data verification by independent agencies. This achievement reaffirms CATL’s commitment to providing customers with sustainable and high-quality battery solutions. With an overall carbon footprint of 49 kgCO2eq/kwh across both pilots, CATL demonstrated its dedication to reducing emissions throughout the battery lifecycle. Furthermore, strong performance across all battery passport criteria highlights CATL’s commitment to transparency, traceability, and environmental responsibility. By prioritizing sustainability, CATL aims to deliver value to customers while contributing to a greener future.

CATL remains committed to the development of GBA battery passports as a tool to enhance product transparency, safety, and sustainability. This initiative aligns with CATL’s sustainable development vision, promoting transparency in product carbon footprint and ESG performance. By participating in the GBA battery passport development and advocacy, CATL aims to contribute to the establishment of global standards for battery industry sustainability, bridging regulatory gaps and fostering a greener future.

Beyond battery passports, CATL strives to actively contribute towards the development of industry standards and best practices. The company’s nine carbon-neutral factories and innovative tools like CCMS and CREDIT demonstrate its dedication to reducing its environmental footprint.

Commenting on the launch, Inga Petersen, Executive Director of the GBA said: “We are thrilled with the results of the 2024 Battery Passport pilots and congratulate all participating organisations for this major achievement. Having the world’s leading cell manufacturers mobilize their supply chains, work pre-competitively and report on harmonised sustainability expectations represents an unprecedented commitment to greater transparency and sustainability in the battery industry as captured in the 2030 GBA Vision.”

Jiang Li, Vice President and Board Secretary of CATL, said: “The future of the battery industry lies in collaborative efforts to ensure sustainability and circularity. CATL is proud to be at the forefront of these efforts. Through our participation in the Battery Passport initiative and our active engagement in the GBA, we are shaping a more sustainable future for the battery sector.”

 

SOURCE Contemporary Amperex Technology Co., Limited (CATL)

Continue Reading

Technology

Aulisa® Medical Expands Access with New Leasing Options for Procuring Advanced Monitoring Solutions

Published

34 mins ago

on

November 8, 2024

By

PALO ALTO, Calif., Nov. 7, 2024 /PRNewswire/ — Aulisa® Medical USA, Inc., a leader in FDA-cleared, wearable, wireless continuous vital sign monitoring technology, proudly announces the launch of flexible leasing options for its state-of-the-art monitoring solutions. This strategic move underscores Aulisa’s mission to bring the latest in healthcare technology to more providers and settings, ensuring that patient care remains efficient, effective, and accessible.

In today’s healthcare landscape, staying at the forefront of medical technology is essential for providing high-quality patient care. Yet, budget constraints and high upfront costs can make this challenging for many hospitals, clinics, and specialized care facilities. Aulisa’s new leasing plans are designed to provide easy and flexible financing alternatives for healthcare facilities to acquire advanced Aulisa® Guardian Angel monitoring solutions without financial strain. By offering these options, Aulisa helps providers maintain optimal care standards while managing expenses more efficiently.

“Offering leasing options is a natural extension of our commitment to enhancing patient safety and supporting healthcare professionals,” said Augustine (Augie) Lien, founder and CEO of Aulisa Medical USA, Inc. “We want to remove the barriers that prevent facilities from accessing the tools they need to deliver exceptional care. By easing financial constraints, we empower providers to stay equipped with cutting-edge technology that can make a real difference in patient outcomes.”

Comprehensive Monitoring Solutions for Every Patient-care Setting
Aulisa’s Guardian Angel® CMPM (Centralized Multiple Patient Monitoring) System has set a high standard in patient monitoring by delivering real-time data on oxygen saturation (SpO2), pulse rate (PR), and body temperature. Now available with flexible leasing options, this system provides unparalleled support to healthcare professionals who need to monitor multiple patients simultaneously, improving workflow efficiency and responsiveness in critical care settings like ICUs and NICUs.

Key Advantages of Leasing Equipment for Healthcare Facilities
Leasing Aulisa’s advanced monitoring systems presents numerous advantages that resonate with the needs of healthcare facilities. Monthly leasing plans allow institutions to allocate funds more efficiently by spreading out costs, avoiding significant upfront expenditures. This model provides financial predictability, as fixed rates prevent budget surprises and enable better long-term planning. Additionally, leasing offers the flexibility to upgrade equipment during the lease term, ensuring that facilities continue to benefit from the latest advancements without the burden of repurchasing.

The immediate access to new technology that leasing offers can enhance patient care significantly. Facilities can implement state-of-the-art monitoring systems quickly, supporting faster and more informed decision-making in patient treatment. Leasing also provides potential tax benefits, as lease payments may be deductible and can improve cash flow by preserving existing lines of credit for other critical investments.

Commitment to Innovation and Accessibility
Aulisa’s introduction of leasing options reaffirms its dedication to innovation and the accessibility of critical monitoring technology. From hospital ICUs and NICUs to specialized clinical settings, Aulisa’s FDA-cleared solutions are designed to ensure reliable, high-quality patient monitoring that healthcare providers can trust.

To learn more about the Guardian Angel® CMPM System and other Aulisa Medical products, visit:
www.aulisa.com/products/cmpm
www.aulisa.com/collections/guardian-angel-remote-gateway-systems

For more information about Aulisa’s leasing options, visit: http://aulisamedicalusainc.firstcitizensef.com or contact the team directly at information@aulisa.com.

About Aulisa Medical
Head-quartered in Silicon Valley, Aulisa® Medical is a leading medical technology company founded by serial medical technologies entrepreneur, Augustine (Augie) Lien. The company specializes in developing wireless, wearable monitoring systems that provide continuous, cloud-based vital sign data in both clinical and home environments. Through the development of new healthcare innovations, Aulisa® continues to grow the application of digital health technologies that empower both consumers and healthcare providers, incorporating Artificial Intelligence (AI) technologies that can detect adverse events and potentially save lives.

Media Contact:
Kyle Thompson, Vice President of Sales & Marketing
Email: kyle.thompson@aulisa.com
Direct: (650) 387-0001
www.aulisa.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/aulisa-medical-expands-access-with-new-leasing-options-for-procuring-advanced-monitoring-solutions-302299474.html

SOURCE Aulisa Medical USA, Inc.

Continue Reading

Trending